Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28

Details for Australian Patent Application No. 2008323853 (hide)

Owner Dana-Farber Cancer Institute, Inc. Beth Israel Deaconess Medical Center

Inventors Kufe, Donald; Avigan, David

Agent Cullens

Pub. Number AU-A-2008323853

PCT Pub. Number WO2009/062001

Priority 61/002,538 08.11.07 US

Filing date 7 November 2008

Wipo publication date 14 May 2009

International Classifications

C12N 5/12 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Fused cells, e.g. hybridomas

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

C12N 5/16 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Animal cells

G01N 33/00 (2006.01) Investigating or analysing materials by specific methods not covered by groups

Event Publications

10 June 2010 PCT application entered the National Phase

  PCT publication WO2009/062001 Priority application(s): WO2009/062001

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008323856-Resealable beverage can end and methods relating to same

2008323852-Wall block with weight bearing pads and method of producing wall blocks